Tomita

What Tomita does

Tomita Pharmaceutical Co., Ltd. (富田製薬株式会社) is a privately held Japanese inorganic chemicals manufacturer founded in 1893, headquartered in Naruto, Tokushima, with 638 employees as of end of April 2026 and annual revenue of approximately 20.60 billion yen (~$135-140M USD) as of April 2025. The company operates four production facilities across Tokushima and Kawasaki, Japan, and a sales representative office in New Jersey, USA, distributing its products through direct B2B sales offices in Tokyo and Osaka. It remains family-owned, with CEO Yoshihiro Tomita and Executive Vice President Kohei Tomita representing the founding family.

The company's core technology is inorganic chemical synthesis and particle control, with proprietary know-how in producing mineral-based functional materials. Its flagship product, the FLORITE® calcium silicate series, uses a unique petaloid crystal structure delivering 3-5x liquid absorption, compressibility, and API-stabilization functionality. The portfolio extends across pharmaceutical APIs and excipients (calcium gluconate, magnesium sulfate, sodium chloride meeting JP/USP/NF standards), food additives (Ferrsorb® ferric pyrophosphate, BRISKOIL® oil refining agents), cosmetic raw materials, specialty industrial adsorbents (TOMITA-AD series), and hydroxyapatite biomaterials. The company also developed the world's first powdered dialysate (KIDOLIME T-30) for kidney dialysis therapy and jointly produces Marine Art powdered artificial seawater with Senju Pharmaceutical. Tomita holds an unusually broad regulatory stack — GMP, JP, USP, NF, JPE, FDA DMF, ICHQ3D, self-affirmed GRAS for FLORITE grades, Halal, Kosher, FSSC22000, NSF, and ISO/ASTM — supporting sales into pharmaceutical, nutraceutical, food, and medical-device customers globally.

Tomita makes money through B2B quote-based sales of ingredients and excipients across four verticals (pharmaceuticals, food, cosmetics, specialty chemicals) under a one-time license/spot-purchase model. Customer acquisition relies on enterprise field sales through Tokyo, Osaka, and Naruto offices, supported by participation in major international trade shows — CPHI Frankfurt/Milan/Barcelona, AAPS PharmaSci 360 (US), Supply Side West, and Food Development Expo Japan. Pricing is private and contract-based with no public rate cards, consistent with custom-specification B2B ingredient supply. The company shows no external funding rounds, no institutional investors, and no M&A activity, operating as a self-funded, debt-light specialty manufacturer.

Name

Tomita

Legal name

Tomita Pharmaceutical Co., Ltd.

Website

https://tomitaph.co.jp

Company type

Private

Founded year

1893

Operating status

Operating

Headcount range

11–50 employees

Short description

Tomita Pharmaceutical Co., Ltd. is a 133-year-old Japanese family-owned inorganic chemicals manufacturer producing pharmaceutical APIs, excipients, food additives, cosmetics ingredients, and specialty industrial chemicals under multiple global certifications, serving B2B customers worldwide through direct sales and trade-show channels.

Ownership category

akta.pro rank

Product category

Pharmaceutical Excipients & Specialty Chemicals

NAICS

Ground or Treated Mineral and Earth Manufacturing (327992), All Other Nonmetallic Mineral Product Manufacturing (32799)

SIC

Industrial Inorganic Chemicals (2810), Miscellaneous Chemical Products (2890)

akta.pro primary industry

Specialty Surfactants & Performance Additives (IMAEABAL)

akta.pro secondary industries

Talc & Pyrophyllite (IMAEAFAC), Mineral/Particulate Thickeners (Silicates, Clays, Calcium Carbonate as texturizers) (AFAJAMAJ)

Keywords

• Pharmaceutical excipients
• Inorganic mineral compounds
• Food fortification ingredients
• Calcium silicate manufacturing
• Specialty chemical production

Headquarters

HQ city

Naruto

HQ country

Japan

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Substances and Additives: B2B sales of active pharmaceutical ingredients (APIs) and excipients to pharmaceutical manufacturers. Products include calcium chloride hydrate, calcium gluconate monohydrate, magnesium sulfate heptahydrate, sodium chloride, and FLORITE calcium silicate series. Compliance with JP, USP, and ICHQ3D guidelines.
2. Food Additives and Nutritional Ingredients: Sales of mineral-based food additives including calcium salts, iron fortification ingredients (Ferrsorb), salt products (Tomita Salt, Naruto Roasted Salt), and functional ingredients to food manufacturers.
3. Cosmetic Raw Materials: Supply of mineral-based ingredients and functional materials like FLORITE for cosmetics applications including foundation base materials, fragrance carriers, and powder stabilizers.
4. Specialty Chemicals: Sales of industrial无机化学 products including moisture conditioning agents (calcium chloride, anhydrous magnesium sulfate), oil refining agents (BRISKOIL series), adsorbents (TOMITA-AD series), and hydroxyapatite for biomaterials.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels8 records

Core offering

Tomita Pharmaceutical Co., Ltd. manufactures and sells inorganic mineral-based functional materials for pharmaceutical, food, cosmetic, and specialty chemical applications. Its product portfolio spans pharmaceutical active ingredients and excipients (including the proprietary FLORITE® calcium silicate series), food additives (calcium, iron, and magnesium compounds; branded salts), cosmetic raw materials (titanium oxide), specialty chemicals (oil refining agents, adsorbents, hydroxyapatite biomaterials), and dialysis-related products (KIDOLIME powdered dialysate and Marine Art artificial seawater).

Product overview

Tomita Pharmaceutical Co., Ltd. is an inorganic chemicals manufacturer specializing in pharmaceutical substances and additives, food additives, cosmetic raw materials, and industrial specialty chemicals. The company's core product lines include the FLORITE® series of multifunctional porous calcium silicate excipients with unique petaloid crystal structures for pharmaceuticals, food, and cosmetics; the BRISKOIL® series of magnesium silicate oil refining agents; the TOMITA-AD series of adsorbents; Ferrsorb® ferric pyrophosphate nutritional ingredients; and Hydroxyapatite biomaterials. The company also produces powdered dialysate (KIDOLIME) for dialysis therapy, food-grade salts under the Tomita Salt and Naruto Hama brands, and maintains pharmaceutical API products including calcium gluconate, magnesium sulfate, and sodium chloride meeting JP/USP standards. The portfolio is organized around mineral-based inorganic chemistry applications across pharmaceuticals, food, cosmetics, and specialty industrial chemicals.

Differentiator

Problem solved

Functional benefit

Brands

• FLORITE®: Multifunctional porous calcium silicate excipient series for pharmaceuticals, food, and cosmetics with unique petaloid crystal structure for liquid absorption and tableting applications.
• BRISKOIL®
• TOMITA-AD Series
• Ferrsorb®
• KIDOLIME T-30
• Marine Art
• Tomita Salt / トミタソルト

Products and services

• FLORITE® Series (Calcium Silicate Excipients) Multifunctional porous calcium silicate excipients with unique petaloid crystal structure offering liquid absorbency (~5x own weight), compressibility, and moldability for pharmaceutical, food, cosmetic, and industrial applications. Includes FLORITE R, FLORITE PS-200, FLORITE PS-10 (NF), FLORITE R-JPE (JPE), FLORITE R-NF (NF), FLORITE H (low aluminum), and FLORITE A-1 (hydrated silicon dioxide) variants.
• Pharmaceutical APIs — Calcium Chloride Hydrate, Calcium Gluconate Monohydrate, Magnesium Sulfate Heptahydrate, Sodium Chloride High-purity active pharmaceutical ingredients meeting Japanese Pharmacopoeia (JP) and USP standards for pharmaceutical formulation, including specialized sodium chloride grades for artificial dialysis. Sold to pharmaceutical manufacturers as GMP-compliant mineral APIs.
• Pharmaceutical Excipients — Aluminium Acetate (cross-linking agent) and Aluminium Sodium Silicate Aluminium acetate cross-linking agent meeting in-house standards and aluminium sodium silicate excipient meeting in-house standards and European Pharmacopoeia specifications, supplied to pharmaceutical manufacturers for tablet and formulation applications.
• BRISKOIL® Series — Magnesium Silicate Oil Refining Agents (BRISKOIL MT, BRISKOIL SMN, BRISKOIL SMW) Magnesium silicate oil refining agents for functional oils and fats processing, offering high deacidifying performance (BRISKOIL MT), low bulk density for excellent filtration handling (BRISKOIL SMN), and high decolorizing ability (BRISKOIL SMW). Sold to food ingredient and edible oil processors.
• Ferrsorb® (Ferric Pyrophosphate Nutritional Ingredient) Specialty ferric pyrophosphate with controlled dissolution behavior — reduced dissolution in gastric pseudo-liquid (pH 1.2) and improved dissolution in duodenal pseudo-liquid (pH 3.0) — delivering approximately 2.4x higher iron elution in the duodenum versus conventional ferric pyrophosphate, with improved dispersion stability in liquids. Sold to food and dietary supplement manufacturers.
• Food-Grade Mineral Nutritional Ingredients (Calcium Carbonate, Calcium Hydroxide, Magnesium Oxide, Magnesium Gluconate, Magnesium Sulfate variants, Copper Gluconate, Zinc Gluconate, Dibasic Calcium Phosphate Anhydrous) Food-additive-grade mineral compounds for nutritional fortification and processing applications, meeting FCC, JSFA, and other food chemical standards. Includes calcium carbonate for calcium supplementation, calcium hydroxide for water quality control in mineral water and brewing, and magnesium/zinc/copper gluconates for fortification.
• TOMITA-AD Series Adsorbents (TOMITA-AD500 Hydrotalcite, TOMITA-AD200P Aluminium Hydroxide, TOMITA-AD610 Magnesium Silicate) Spray-dried spherical adsorbents for removing acidic components and impurities from gases and liquids, chemically stable in organic and aqueous solvents and against heat, oxygen, humidity, and light. TOMITA-AD500 (hydrotalcite, layered double hydroxide), TOMITA-AD200P (aluminium hydroxide, 64 m²/g surface area), TOMITA-AD610 (magnesium silicate, 430 m²/g surface area) for industrial adsorption applications.
• Dehumidifying Agents (Calcium Chloride and Anhydrous Magnesium Sulfate, including OT-S grade) Moisture conditioning agents for industrial moisture absorption. Anhydrous magnesium sulfate absorbs approximately its own weight in water and is used as a humidity regulator; the OT-S grade is blended with calcium stearate to prevent aggregation in processing applications.
• Hydroxyapatite Biomaterials (Hydroxyapatite C, HD, FP) High-purity hydroxyapatite biomaterials for medical device applications including abrasives, plasma thermal spraying, artificial bone, dental implants, and bone fillers. Hydroxyapatite HD is used for coating PEEK and Ti alloys (ASTM/ISO compliant); Hydroxyapatite FP forms high-strength films with 63% crystallinity in thermal spraying and conforms to ISO13779-6. Sold to medical device manufacturers.
• Cosmetic: Titanium Oxide (UV Protection) Titanium oxide UV protective agent for cosmetics, supplied to cosmetics manufacturers for full-range UV protection applications.
• Tomita Salt Series (Tomita Salt K30, 70M, 100M, E70M, E100M, Naruto Hama) Food-grade salt products in multiple particle sizes for various food applications, including Naruto Hama salt variants. Sold to food manufacturers.
• Naruto no Yakishio (Naruto Burned Salt — 250M, No.10, fine powder, PC variants) Premium burned salt from the Naruto region in various particle sizes, including anti-caking agent variants, sold to food manufacturers and processors.
• KIDOLIME T-30 (Powdered Dialysate) World's first powder-form dialysate for dialysis therapy, developed using advanced inorganic chemical synthesis, coating, granulation, and mixing technologies. Coating electrolyte components around a sodium chloride core enables convenient preparation of dialysis fluid and has expanded dialysis therapy accessibility across Japanese hospitals and dialysis centers.
• Marine Art (Powdered Artificial Seawater) Powdered artificial seawater developed in collaboration with Senju Pharmaceutical Co., Ltd. for laboratory and research applications; Tomita manufactures using proprietary formulation technology while Senju handles distribution (partnership since 1990).

Quantifiable outcome

• FLORITE absorbs approximately 5 times its own weight in liquid
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered minor and core.

• Naruto University of Education (鳴門教育大学)minorGTM or Marketing Partner · 1 June 2025Naming rights partnership for university library. Library renamed 'Tomita Pharma Manabi no Library' (富田製薬まなびの図書館). Contract period: June 1, 2025 to March 31, 2028. Regional community engagement initiative supporting education in Naruto region.
• Senju Pharmaceutical Co., Ltd. (千寿製薬)coreStrategic or Co-development Partner · 1 January 1990Joint development partnership for powdered artificial seawater 'Marine Art'. Tomita responsible for manufacturing using proprietary formulation technology while Senju handles product distribution. Partnership established in 1990 and continues to present.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Freund Corporation: Japanese specialty chemical company focused on pharmaceutical excipients, granulation, and coating technology. Comparable in pharma excipient portfolio depth and Japan-centric B2B enterprise sales motion.
• Imerys: Global leader in mineral-based specialty additives (calcium carbonate, talc, perlite), with strong pharmaceutical and food-grade portfolios. Most direct competitor to Tomita's calcium silicate and magnesium silicate functional materials in industrial and life-sciences applications.
• Fuji Chemical Industries: Japanese manufacturer of pharmaceutical excipients, functional food ingredients, and active pharmaceutical ingredients — most direct Japanese comparable to Tomita in inorganic APIs, calcium-based compounds, and specialty excipients.
• Huber Engineered Materials (J.M. Huber): Specialty silica, calcium silicate, and alumina hydrate manufacturer serving pharma, food, and industrial customers. Closest US-based analog to FLORITE in porous calcium silicate excipients and tableting aids.
• Omya: Swiss private producer of calcium carbonate and mineral-based functional fillers with deep food, pharma, and personal care customer bases. Directly comparable to Tomita in mineral-functional-material positioning and grade-level customization.
• Minerals Technologies Inc. US-listed specialty minerals company producing precipitated calcium carbonate, bentonite, and talc-based products for pharma, food, and industrial markets. Comparable product architecture to Tomita's FLORITE and BRISKOIL ranges and similar B2B excipient go-to-market.

Broad incumbents

• Nippon Chemical Industrial: Japanese inorganic chemicals producer with phosphor, barium, and chromium compound lines serving pharma and industrial customers. Comparable in inorganic chemistry heritage and regulatory-compliant manufacturing.
• Sakai Chemical Industry: Long-established Japanese inorganic chemicals manufacturer with broader titanium dioxide, barium, and catalyst portfolios. Overlaps with Tomita in specialty inorganic chemistry and Japan-anchored B2B sales to industrial and pharma customers.
• Resonac (formerly Showa Denko): Large Japanese specialty chemical conglomerate with inorganic materials, electronic materials, and pharma adjacencies. Overlaps with Tomita in inorganic specialty materials and serves global pharma/food accounts.

Regional players

• Daito Pharmaceutical: Japanese manufacturer of pharmaceutical raw materials and intermediates with comparable domestic customer base and regulatory positioning. Relevant as a regional Japanese pharma-input peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/profile.php

Compliance20 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tomita